Home
AARD
AARD News

Latest Aardvark Therapeutics Inc. (AARD) News on November 17, 2025

MT Newswires

3 days ago

RBC Cuts Price Target on Aardvark Therapeutics to $18 From $19, Keeps Outperform, Speculative Risk

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

GlobeNewswire

3 days ago

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

5 days ago

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Datadog, Trade Desk upgraded: Wall Street's top analyst calls

The Fly

10 days ago

Datadog, Trade Desk upgraded: Wall Street's top analyst calls

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

GlobeNewswire

13 days ago

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

13 days ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

GlobeNewswire

14 days ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

GlobeNewswire

a month ago

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment

Insider Monkey

a month ago

Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment

MT Newswires

a month ago

Aardvark Therapeutics Reaches Alignment With FDA on Broadening Phase 3 Prader-Willi Syndrome Trial Population

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

GlobeNewswire

a month ago

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

GlobeNewswire

5 months ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet

Zacks

5 months ago

Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

GlobeNewswire

6 months ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire

6 months ago

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

GlobeNewswire

6 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

MT Newswires

7 months ago

Top Premarket Gainers

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

GlobeNewswire

8 months ago

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Investor's Business Daily

8 months ago

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month

Insider Monkey

8 months ago

Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month

Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently

Insider Monkey

8 months ago

Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently

Share on Social Networks: